Wada, Yamato
Nithichanon, Arnone
Nobusawa, Eri
Moise, Leonard
Martin, William D.
Yamamoto, Norio
Terahara, Kazutaka
Hagiwara, Haruhisa
Odagiri, Takato
Tashiro, Masato http://orcid.org/0000-0001-8133-1263
Lertmemongkolchai, Ganjana
Takeyama, Haruko
De Groot, Anne S.
Ato, Manabu
Takahashi, Yoshimasa
Article History
Received: 17 November 2016
Accepted: 29 March 2017
First Online: 28 April 2017
Change Date: 8 October 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: W.M. and A.D.G. are senior officers and majority shareholders at EpiVax, Inc. L.M. is an employee and holds stock options at EpiVax. These authors acknowledge a potential conflict of interest and attest that the work contained in this report is free of any bias that might be associated with the commercial goals of the company. W.M., A.D.G., M.A., and Y.T. are named inventors on patent applications covering Opt1 H7 HA. Other authors declare no competing financial interests.